相关实验视频
Updated: Jun 26, 2025

05:23
Investigating Migraine-Like Behavior Using Light Aversion in Mice
Published on: August 11, 2021
3.8K
切换CGRP (r) 偏头痛中的MoAbs:有什么证据?
William David Wells-Gatnik1, Paolo Martelletti2
1Department of Clinical and Molecular Medicine, Sapienza University, Lazio, Rome, Italy.
Expert opinion on biological therapy
|May 10, 2024
概括
许多患者停止CGRP单克隆抗体 (mAb) 治疗偏头痛. 切换到不同的CGRP mAb可能是一个选择,但目前对其有效性的证据有限.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 偏头痛影响全球数百万人,CGRP单克隆抗体 (mAbs) 提供了一种新的预防性治疗方法.
- 由于各种原因,大约50%的患者停止CGRP mAb治疗.
- 对于停止CGRP mAb治疗的患者,存在有限的治疗替代方案.
研究的目的:
- 审查和总结现有关于在先前停药后切换到另一种CGRP mAb的疗效的数据.
- 为了解决在偏头痛管理中了解替代治疗策略的临床需求.
主要方法:
- 进行了全面的数据库搜索,使用与"CGRP单克隆抗体切换"和"CGRP单克隆抗体切换"相关的术语.
- 编译和分析了所有关于切换CGRP mAbs有效性的文献和数据.
主要成果:
- 目前关于切换CGRP mAbs疗效的数据很少,并且继续演变.
- 专家意见与欧洲头痛联合会关于CGRP mAb切换有效性的证据不足的立场一致.
结论:
- 没有足够的临床数据来确定切换CGRP mAbs对偏头痛预防的有效性.
- 进一步的研究和数据收集对于确定CGRP mAb切换在停止初始治疗的患者的治疗价值至关重要.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
249
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
249
Cholinergic Receptors: Muscarinic
2.1K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
2.1K
Drugs Acting on Autonomic Ganglia: Blockers
1.0K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.0K

